Kisaco Life Sciences Strategy Summit on IP & Exclusivity 2024 

Fish & Richardson attorneys Moritz Ammelburg, Christina Brown-Marshall, and Brian Coggio will speak at the Life Sciences Strategy Summit on IP & Exclusivity on October 9 and 10. 

Fish is proud to support the Life Sciences Strategy Summit on IP & Exclusivity, a premier life sciences intellectual property (IP) event that brings together leading pharmaceutical and biotech professionals for practical discussions on the protection of pharmaceutical drugs based on patent and regulatory exclusivities. Session details are below. 

G1/22 and G2/22: EBA Decision on Entitlement to Claim Priority and the Interaction With U.S. Patents 

Wednesday, October 9 | 4:30 p.m. CEST 

This roundtable session will discuss the interesting points raised by this decision and how they should affect your IP strategy. The roundtable leader will discuss the opinions regarding whether the European Patent Office (EPO) is competent to assess a party’s entitlement to claim priority. Finally, they will look at the USA and discuss whether party B can rely on a priority claim in an application under the Patent Cooperation Treaty (the PCT-application) to a U.S. application filed by party A. 

Speaker:

• Moritz Ammelburg, Principal, Fish & Richardson

Patentability Concerns for Life Science Products in Europe and the USA: Plausibility and Enablement 

Thursday, October 10 | 11:30 a.m. CEST 

Following the issuance of the G2/21 decision by the EPO Boards of Appeal (BOA), there have been several cases that have further tested the clarity of the subject. This industry panel session will discuss these topics and help you understand how they are relevant for the small molecule life sciences industry: 

• Understand the decisions from T116/18 in Sumitomo v. Syngenta (2023).
• Compare this with T681/21 in Unilever v. Procter & Gamble (2023) and understand whether the case law is diverging from the G2/21 decision from the EPO BOA.  
• Make a comparison with the enablement position in the USA following the Amgen v. Sanofi/Regeneron Supreme Court case (2023). 

Speakers: 

• Tamaris Bucher, Principal Patent Attorney, Novartis 
• Denis Schertenleib, Partner, Schertenleib Avocats 
• Christina Brown-Marshall, Principal, Fish & Richardson 
• Adrian Chew, Of Counsel, Bristows 
  

Finding Safe Harbor (and the Bolar Exemption) and Its Impact Upon Your Life Science Legal Strategy 

Thursday, October 10 | 3:00 p.m. CEST 

The bolar exemption and safe harbor regulations set out the legal provisions allowing generic manufacturers to perform experiments and tests necessary for regulatory approval. This industry-led session will highlight some of the core case law in Europe and the USA and determine your optimal IP strategy.  

• Discover the divergences between the Bolar exemptions across Europe and the Unified Patent Court (UPC). 
• Understand the interaction between the supplementary protection certificate (SPC) manufacturing waiver and the bolar exemption.  
• Determine the latest update from the European Commission on the potential for content-wide harmonization: How will this impact market authorization strategies for generic products? Will the UK and the UPC follow?  
• Understand the scope and history of protection afforded by safe harbor in the USA. 

Speaker: 

• Brian Coggio, Of Counsel, Fish & Richardson

For more information click here.